Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
02/2000
02/08/2000US6022886 Endothelin receptor antagonists
02/08/2000US6022885 Pyrrolidine and thiazole derivatives with antibacterial and . metallo-.beta-lactamase inhibitory properties
02/08/2000US6022884 Substituted pyridine compounds and methods of use
02/08/2000US6022883 Heterocyclyloxybenzoylguanidines
02/08/2000US6022880 Substituted pyridylamino indoles
02/08/2000US6022879 Bathocuproine treatment of neurologic disease
02/08/2000US6022878 Inhibitors of rotamase enzyme activity
02/08/2000US6022877 Use of (+)-α-(2,3-dimethoxyphenyl-1-[2-(4-fluorophenyl)ethyl]-4-piperidin emethanol in treating depressive disorders and bipolar disorders
02/08/2000US6022876 L-β-dioxolane uridine analogs and methods for treating and preventing Epstein-Barr virus infections
02/08/2000US6022875 Use of substituted 2,4-imidazolidinedione compounds as analgesics
02/08/2000US6022873 Metalloproteinase inhibitors
02/08/2000US6022868 Substituted azacyclic or azabicyclic compounds
02/08/2000US6022867 Method of administering vitamin E to animals and compositions containing tocopheryl phosphates and salts thereof for animals
02/08/2000US6022866 Use of hyaluronic acid and forms to prevent arterial restenosis
02/08/2000US6022862 Use of pseudopterosins for promoting wound healing
02/08/2000US6022855 Novel variants of the naturally-occurring protease inhibitor, alpha1-antitrypsin and derived peptides comprising a sequence of-arg-xaa-xaa-arg-; viricides; bactericides; blocking of endoproteolytic activation of a bacterial toxin
02/08/2000US6022851 Cyclic polypeptides for treatment and prophylaxis of antibiotic-resistant bacterial infectious diseases by administration with an excipient
02/08/2000US6022850 Use of hemoglobin in the treatment of stroke
02/08/2000US6022565 Extract of jewelweed (impatiens species such as impatiens capensis, impatiens biflora, impatiens balsamea, and impatiens pallida), extract of plantain leaf, and aqueous colloidal dispersion of subdivided whole oat grains; poison ivy
02/08/2000US6022564 Method for producing a microparticle
02/08/2000US6022563 Phenylbutazone carrier formulation
02/08/2000US6022558 Transdermal preparations of oxicams
02/08/2000US6022556 Swellable wound dressing materials
02/08/2000US6022555 Animal feed containing carboxylic acids
02/08/2000US6022551 Rapidly disinfects surfaces including the hands; comprising alcohol, specific antimicrobial(s) such as benzethonium chloride, and cocophosphatidyl-dimonium chloride, and a copolymer carbomer thickener
02/08/2000US6022545 Usage of pathogen-killing foams
02/08/2000US6022542 Polypeptide which serves as reagent in diagnostic kit for detecting an anti-herpesvirus antibody present in a biological sample; kaposi's sarcoma (ks) and retroperitoneal fibromatosis (rf)
02/08/2000US6022538 Administering adriamycin or cisplatin, and cell therapy cells modified by in vitro treatment with a cytokine and gamma irradiation at a dose to irreversibly arrest cell proliferation but not interfere with the cytotoxic activity
02/08/2000US6022533 Tablets containing anion exchange resin
02/08/2000US6022527 Method of treating lung diseases with uridine 5'-diphosphate and analogs thereof
02/08/2000US6022379 Hair dye
02/08/2000CA2234364C Compositions for inhibiting platelet aggregation
02/08/2000CA2150016C Pyrrolopyrimidines as crf antagonists
02/08/2000CA2127677C 2-bromo- and 2-nitroxy derivatives of 3-bromo- and 3.3-dibromo-4-oxo-azetidines, processes for the preparation thereof and use thereof
02/08/2000CA2090942C Anti-tumour compounds containing quinazoline and tetrazole rings
02/08/2000CA2014467C 3-substituted-2-oxindole derivatives
02/08/2000CA2014379C Compounds
02/08/2000CA2006387C Xanthine derivatives with adenosine-antagonistic activity
02/08/2000CA2004597C Topical formulations and transdermal delivery systems containing 1-isobutyl-1h-imidazo-[4,5-c]quinoline-4-amine
02/08/2000CA2004064C Supported drugs with increased dissolution rate, and a process for theirpreparation
02/08/2000CA1340892C Bisplatinum complexes as chemotherapeutic agents
02/07/2000CA2279732A1 Method of inhibition of human glycogen phosphorylase
02/06/2000CA2279747A1 Estrogen agonists/antagonists
02/03/2000WO2000005395A1 Method for obtaining fatty acids from biomass by combined in-situ extraction, reaction and chromatography using compressed gases
02/03/2000WO2000005394A1 Vectors derived from baculovirus and use for transferring nucleic acids into nerve cells of vertebrates
02/03/2000WO2000005393A2 A polynucleotide comprising a ubiquitous chromatin opening element (ucoe)
02/03/2000WO2000005388A1 Genes of the dead box protein family, their expression products and use
02/03/2000WO2000005362A1 Mekk1(serine threonine kinases)-interacting fha (forkhead associated domain) protein 1 (mif1)
02/03/2000WO2000005361A1 Human sbpsapl gene with homology to the prosaposin family of neurotrophic factors
02/03/2000WO2000005359A1 Use of prohibitin rna in treatment of cancer
02/03/2000WO2000005358A1 Methods for purifying nucleic acids
02/03/2000WO2000005348A1 Pneumococcal nrdg protein
02/03/2000WO2000005269A1 Polymer complexes of glucuronoglucanes
02/03/2000WO2000005259A1 Secreted cysteine rich protein-6 (scrp-6)
02/03/2000WO2000005244A1 HUMAN BOMBESIN RECEPTOR SUBTYPE-3sb
02/03/2000WO2000005239A1 Novel 6-deoxy erythromycin derivatives, method for preparing same and use as medicines
02/03/2000WO2000005232A1 Heterocyclic compounds as inhibitors of rotamase enzymes
02/03/2000WO2000005231A1 Fkbp inhibitors
02/03/2000WO2000005229A1 Phenylindole derivatives as 5-ht2a receptor ligands
02/03/2000WO2000005225A1 Biphenyl derivatives
02/03/2000WO2000005224A2 Heterocyclic derivatives and their use as integrin inhibitor
02/03/2000WO2000005223A2 Heterocyclic derivatives and their use as integrin inhibitors
02/03/2000WO2000005219A1 Phthalazine derivatives as phosphodiesterase 4 inhibitors
02/03/2000WO2000005218A1 Phthalazine derivatives phosphodiesterase 4 inhibitors
02/03/2000WO2000005217A1 Imidazole compounds and their use as adenosine deaminase inhibitors
02/03/2000WO2000005216A1 Il-8 receptor antagonists
02/03/2000WO2000005210A1 N,n-substituted cyclic amine derivatives
02/03/2000WO2000005207A1 Substituted phenylamidines with antithrombotic action
02/03/2000WO2000005206A1 Arylpiperazine derivatives useful as uro-selective alpha-1-adrenoceptor blockers
02/03/2000WO2000005201A1 N-benzocycloalkyl-amide derivatives and their use as medicaments
02/03/2000WO2000005196A1 α-AMINO ACID PHENYL ESTER DERIVATIVES
02/03/2000WO2000004954A2 Novel urokinase inhibitors
02/03/2000WO2000004939A1 Dental pin
02/03/2000WO2000004937A1 Flat flexible materials
02/03/2000WO2000004926A2 Conjugates for treating inflammatory disorders and associated tissue damage
02/03/2000WO2000004925A1 Slow release formulations comprising anionic polysaccharide
02/03/2000WO2000004924A1 Composition and pharmaceutical dosage form for colonic drug delivery using polysaccharides
02/03/2000WO2000004923A1 Scrp-5: secreted cysteine rich protein-5
02/03/2000WO2000004912A1 Therapeutic agent for dementia, comprising ginseng extract
02/03/2000WO2000004911A1 Bovine excretion extracts having anticancer and anti-inflammatory activity and process for preparing the same
02/03/2000WO2000004908A1 Composite biocidal particles
02/03/2000WO2000004907A1 An antilipemic formulation
02/03/2000WO2000004905A1 Benzoquinolizidine and benzoindolizidine derivatives and therapeutic uses thereof
02/03/2000WO2000004904A1 Pharmaceutical compositions comprising hydroxylansoprazole and uses thereof
02/03/2000WO2000004903A1 The use of cd4-binding small molecules to inhibit hiv infection
02/03/2000WO2000004902A1 Stabilized carvedilol injection solution
02/03/2000WO2000004901A1 Small molecule inhibitors of bcl-2 proteins
02/03/2000WO2000004900A1 Substituted benzimidazole antiviral agents
02/03/2000WO2000004899A1 Ophthalmic compositions for treating ocular hypertension
02/03/2000WO2000004898A1 Ophthalmic compositions for treating ocular hypertension
02/03/2000WO2000004897A1 Bioimplant formulation
02/03/2000WO2000004896A1 Solid preparation containing sparingly soluble nsaids
02/03/2000WO2000004895A2 Nutritional and therapeutic uses of 3-hydroxyalkanoate oligomers
02/03/2000WO2000004894A2 Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate
02/03/2000WO2000004893A2 Imidazoline receptor binding compounds
02/03/2000WO2000004892A2 Coadministration of acat and mmp inhibitors for the treatment of atherosclerotic lesions
02/03/2000WO2000004891A2 Anti-ulcer composition
02/03/2000WO2000004890A1 Use of glucose uptake enhancer for reducing apoptosis
02/03/2000WO2000004889A1 Use of glucose uptake enhancer for reducing post-ischemic injury of the heart
02/03/2000WO2000004888A2 Use of cyclodextrins for the treatment of cerebral ischaemia and central nervous system injury